Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:temple
|
| gptkbp:activities |
estrogen receptor antagonist
|
| gptkbp:appointed_by |
injection
|
| gptkbp:approves |
gptkb:2002
gptkb:FDA |
| gptkbp:availability |
prescription only
|
| gptkbp:can_be_used_with |
other cancer therapies
|
| gptkbp:class |
hormonal therapy
|
| gptkbp:clinical_trial |
Phase III
second-line therapy first-line therapy in some cases |
| gptkbp:contraindication |
pregnancy
hypersensitivity to fulvestrant |
| gptkbp:dosage_form |
solution for injection
|
| gptkbp:education |
lifestyle modifications
recognizing side effects importance of follow-up appointments adherence to dosing schedule |
| gptkbp:formulation |
250 mg/5 m L
|
| https://www.w3.org/2000/01/rdf-schema#label |
Faslodex
|
| gptkbp:indication |
gptkb:hormone_receptor-positive_breast_cancer
|
| gptkbp:ingredients |
gptkb:fulvestrant
|
| gptkbp:interacts_with |
anticoagulants
CY P450 inducers CY P450 inhibitors |
| gptkbp:is_monitored_by |
liver enzymes
blood counts |
| gptkbp:is_used_for |
breast cancer treatment
|
| gptkbp:lifespan |
approximately 50 days
|
| gptkbp:manager |
intramuscular
|
| gptkbp:manufacturer |
gptkb:temple
|
| gptkbp:marketed_as |
multiple countries
|
| gptkbp:pharmacokinetics |
highly protein-bound
inhibits estrogen action |
| gptkbp:population |
postmenopausal women
|
| gptkbp:provides_information_on |
included in breast cancer treatment guidelines
|
| gptkbp:requires |
available online
|
| gptkbp:research |
improved survival rates
reduced disease progression |
| gptkbp:research_focus |
patient quality of life
combination therapies resistance mechanisms new formulations |
| gptkbp:rounds |
hepatic
|
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:side_effect |
fatigue
headache nausea decreased appetite thromboembolic events injection site reactions bone pain hot flashes liver function abnormalities |
| gptkbp:storage |
refrigerated
|
| gptkbp:traded_on |
gptkb:Faslodex
|
| gptkbp:type_of_care |
important for efficacy
|